Logo image of GH

GUARDANT HEALTH INC (GH) Stock Price, Forecast & Analysis

USA - NASDAQ:GH - US40131M1099 - Common Stock

91.355 USD
-1.05 (-1.14%)
Last: 10/31/2025, 1:01:09 PM

GH Key Statistics, Chart & Performance

Key Statistics
Market Cap11.39B
Revenue(TTM)739.02M
Net Income(TTM)-413818000
Shares124.71M
Float119.27M
52 Week High95.88
52 Week Low22.92
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-2.91
PEN/A
Fwd PEN/A
Earnings (Next)02-18 2026-02-18/amc
IPO2018-10-04
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Providers & Services
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Services


GH short term performance overview.The bars show the price performance of GH in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 20 40 60 80 100

GH long term performance overview.The bars show the price performance of GH in the last 1, 2 and 3 years. 1 year 2 years 3 years 100 200 300

The current stock price of GH is 91.355 USD. In the past month the price increased by 50.36%. In the past year, price increased by 301.78%.

GUARDANT HEALTH INC / GH Daily stock chart

GH Latest News, Press Relases and Analysis

GH Competitors/Peers

The largest stocks on the US markets in the "Health Care Services" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
CVS CVS HEALTH CORP 11.15 96.86B
CI THE CIGNA GROUP 8.54 64.80B
LH LABCORP HOLDINGS INC 16.1 21.17B
BTSGU BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 203.25 19.80B
DGX QUEST DIAGNOSTICS INC 18.07 19.72B
FMS FRESENIUS MEDICAL CARE-ADR 13.3 15.69B
HIMS HIMS & HERS HEALTH INC 56.74 10.26B
DVA DAVITA INC 12.28 8.51B
CHE CHEMED CORP 19.82 6.35B
RDNT RADNET INC 211.42 5.85B
BTSG BRIGHTSPRING HEALTH SERVICES 59 5.75B
OPCH OPTION CARE HEALTH INC 17.05 4.12B

About GH

Company Profile

GH logo image Guardant Health, Inc. is a precision oncology company, which engages in the provision of treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. The company is headquartered in Palo Alto, California and currently employs 1,999 full-time employees. The company went IPO on 2018-10-04. The company provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. The company offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.

Company Info

GUARDANT HEALTH INC

3100 Hanover Street

Palo Alto CALIFORNIA 94063 US

CEO: Helmy Eltoukhy

Employees: 1999

GH Company Website

GH Investor Relations

Phone: 18556988887

GUARDANT HEALTH INC / GH FAQ

What does GUARDANT HEALTH INC do?

Guardant Health, Inc. is a precision oncology company, which engages in the provision of treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. The company is headquartered in Palo Alto, California and currently employs 1,999 full-time employees. The company went IPO on 2018-10-04. The company provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. The company offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.


What is the stock price of GUARDANT HEALTH INC today?

The current stock price of GH is 91.355 USD. The price decreased by -1.14% in the last trading session.


Does GUARDANT HEALTH INC pay dividends?

GH does not pay a dividend.


How is the ChartMill rating for GUARDANT HEALTH INC?

GH has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


Can you provide the sector and industry classification for GUARDANT HEALTH INC?

GUARDANT HEALTH INC (GH) operates in the Health Care sector and the Health Care Providers & Services industry.


Can you provide the market cap for GUARDANT HEALTH INC?

GUARDANT HEALTH INC (GH) has a market capitalization of 11.39B USD. This makes GH a Large Cap stock.


What is the next earnings date for GH stock?

GUARDANT HEALTH INC (GH) will report earnings on 2026-02-18, after the market close.


GH Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to GH. When comparing the yearly performance of all stocks, GH is one of the better performing stocks in the market, outperforming 98.42% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

GH Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to GH. Both the profitability and financial health of GH have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

GH Financial Highlights

Over the last trailing twelve months GH reported a non-GAAP Earnings per Share(EPS) of -2.91. The EPS increased by 17.09% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -31.07%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%55.68%
Sales Q2Q%38.5%
EPS 1Y (TTM)17.09%
Revenue 1Y (TTM)31.04%

GH Forecast & Estimates

34 analysts have analysed GH and the average price target is 69.28 USD. This implies a price decrease of -24.17% is expected in the next year compared to the current price of 91.355.

For the next year, analysts expect an EPS growth of 10.91% and a revenue growth 26.22% for GH


Analysts
Analysts85.88
Price Target69.28 (-24.16%)
EPS Next Y10.91%
Revenue Next Year26.22%

GH Ownership

Ownership
Inst Owners99.51%
Ins Owners4.26%
Short Float %6.94%
Short Ratio3.65